Leveraging epigenetics to enhance the efficacy of cancer-testis antigen: a potential candidate for immunotherapy
/in Dendritic Cells, International Publications, Ovarian CancerGlucose Deprivation Induced by Acarbose and Oncolytic Newcastle Disease Virus Promote Metabolic Oxidative Stress and Cell Death in a Breast Cancer Model
/in Breast Cancer, International Publications, Newcastle Disease VirusAn Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors
/in Dendritic Cells, International Publications, Ovarian CancerPersonalized tumor vaccine for pancreatic cancer
/in Dendritic Cells, International Publications, Pancreatic CancerComparison between intratumoral and intravenously administered oncolytic virus therapy with Newcastle disease virus in a xenograft murine model for pancreatic adenocarcinoma
/in International Publications, Pancreatic CancerAvian Paramyxovirus 4 Antitumor Activity Leads to Complete Remissions and Long-term Protective Memory in Preclinical Melanoma and Colon Carcinoma Models
/in Colorectal Cancer, International Publications, Malignant Melanoma, Newcastle Disease VirusDevelopment of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy
/in International Publications, Newcastle Disease VirusDual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model
/in Breast Cancer, Checkpoint-Inhibitors, Dendritic Cells, International PublicationsSafety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial)
/in Dendritic Cells, International Publications, Pancreatic Cancer
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer